Executive Advisor

Michael is an Executive Advisor of Frequency Therapeutics and works closely with FREQ management team to develop corporate and portfolio strategy, and provide guidance on the overall operations of the company. Michael is the former Chief Operating Officer of Frequency. Prior to Frequency, he co-founded Catabasis Pharmaceuticals and served as Chief Scientific Officer, where his contributions helped create several potential new therapeutics and guide the company to an IPO in 2015. During his almost 30-year career, Michael has overseen hundreds of R&D programs and has brought more than 15 new therapeutics from discovery into clinical study to address muscular dystrophy, dyslipidemia, cancer and a variety of metabolic diseases. Michael is the former Senior Vice President of Research for Sirtris Pharmaceuticals, acquired by GlaxoSmithKline in 2008 after an IPO in 2007. He also led the metabolic disease therapeutic area at Pfizer’s Laboratories in La Jolla, California and has had leadership roles at Abbott Laboratories and Eli Lilly. Michael holds a Ph.D. in Chemistry from Case Western Reserve University and completed his postdoctoral study at Harvard University.